Objective: There is evidence that suicidal behavior, among others, is an abnormal response to stress caused by a dysfunction in the activity of hypothalamus-pituitary-adrenal axis, and that cortisol levels are low in a considerable number of people attempting suicide. In this study, we aimed to search for associations of plasma cortisol levels with the clinical characteristics of a group of psychiatric suicide attempters. Method: The cortisol was measured in the morning in 200 psychiatric patients hospitalized after a suicide attempt, with diagnoses of major depressive disorder, bipolar disorder, psychosis, and personality/adjustment disorder, and compared to the levels of 138 healthy controls. Comparisons were also made for diagnostic subgroups and across diagnoses, with regard to depressive symptomatology, mode of attempt, suicide intent, number of attempts, and age. Results: Cortisol levels were significantly lower for the whole group of attempters compared to controls. Furthermore, low cortisol levels characterized attempters with personality/adjustment disorder, higher depressive symptomatology, low suicide intent, non-violent attempt mode, repeated attempts, and of younger age. Conclusions: Certain clinical characteristics were identified in attempters with low cortisol levels. In previous studies, low cortisol levels have been associated with impairments in cognitive control, decision-making, and emotional processing that may lead, in the presence of stressors, to suicidal behavior, frequently with non-fatal outcome. Adding plasma cortisol levels to demographic and psychopathological data may help in identifying a subpopulation of attempters with neurocognitive deficits linked to dysfunction of Hypothalamic-Pituitary-Adrenal-axis activity, with implications for treatment.

Keywords:
Cortisol, Suicide attempt, Psychiatric diagnosis, Violent attempt, Suicide intent, Repeated attempts
1.
Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003; 4: 819–828.
2.
Μann JJ, Currier D: Biological predictors of suicidal behaviour in mood disorders. Neurobiology and the genetics of suicide; in: Wasserman D, Wasserman C (eds): Oxford Textbook of Suicidology and Suicide Prevention. Oxford, Oxford University Press 2009, pp 335–339.
3.
Coryell W, Schlesser M: The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001; 158: 748–753.
4.
Lester D: The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry 1992; 25: 265–270.
5.
Pompili M, Serafini G, Innamorati M, Moller-Leimkuhler AM, Giupponi G, Girardi P, et al: The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. Eur Arch Psychiatry Clin Neurosci 2010; 260: 583–600.
6.
Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, et al: Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry 2005; 57: 336–342.
7.
Jokinen J, Ouda J, Nordstrom P: Noradrenergic function and HPA axis dysregulation in suicidal behaviour. Psychoneuroendocrinology 2010; 35: 1536–1542.
8.
Pitchot W, Hansenne M, Pinto E, Reggers J, Fuchs S, Ansseau M: 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biol Psychiatry 2005; 58: 854–858.
9.
Secunda SK, Cross CK, Koslow S, Katz MM, Kocsis J, Maas JW, et al: Biochemistry and suicidal behavior in depressed patients. Biol Psychiatry 1986; 21: 756–767.
10.
Westrin A, Ekman R, Traskman-Bendz L: Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 1999; 9: 205–211.
11.
Saiz P, Bobes J, Gonzalez M, Cocana I, Gonzalez-Quiros P, Bousono M: Searching for a predictive peripherical biological model in parasuicidal behaviour. Eur Psychiatry 1997; 12: 75–81.
12.
Van Heeringen K, Audenaert K, Van De Wiele L, Verstraete A: Cortisol in violent suicidal behaviour: association with personality and monoaminergic activity. J Affect Disord 2000; 60: 181–189.
13.
Chatzittofis A, Nordstrom P, Hellstrom C, Arver S, Asberg M, Jokinen J: CSF 5-HIAA, cortisol and DHEAS levels in suicide attempters. Eur Neuropsychopharmacol 2013; 23: 1280–1287.
14.
Brunner J, Keck ME, Landgraf R, Uhr M, Namendorf C, Bronisch T: Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. Eur Neuropsychopharmacol 2002; 12: 489–494.
15.
Kim B, Kang ES, Fava M, Mischoulon D, Soskin D, Yu BH, et al: Follicle-stimulating -hormone (FSH), current suicidal ideation and -attempt in female patients with major -depressive disorder. Psychiatry Res 2013; 210: 951–956.
16.
Mcgirr A, Diaconu G, Berlim MT, Turecki G: Personal and family history of suicidal behaviour is associated with lower peripheral cortisol in depressed outpatients. J Affect Disord 2011; 131: 368–373.
17.
O’Connor DB, Ferguson E, Green JA, O’carroll RE, O’connor RC: Cortisol levels and suicidal behavior: a meta-analysis. Psychoneuroendocrinology 2016; 63: 370–379.
18.
Lindqvist D, Isaksson A, Traskman-Bendz L, Brundin L: Salivary cortisol and suicidal behavior – a follow-up study. Psychoneuroendocrinology 2008; 33: 1061–1068.
19.
Keilp JG, Stanley BH, Beers SR, Melhem NM, Burke AK, Cooper TB, et al: Further evidence of low baseline cortisol levels in suicide attempters. J Affect Disord 2016; 190: 187–192.
20.
Shirtcliff EA, Granger DA, Booth A, Johnson D: Low salivary cortisol levels and externalizing behavior problems in youth. Dev Psychopathol 2005; 17: 167–184.
21.
Loney BR, Butler MA, Lima EN, Counts CA, Eckel LA: The relation between salivary cortisol, callous-unemotional traits, and conduct problems in an adolescent non-referred sample. J Child Psychol Psychiatry 2006; 47: 30–36.
22.
Turecki G, Ernst C, Jollant F, Labonte B, Mechawar N: The neurodevelopmental origins of suicidal behavior. Trends Neurosci 2012; 35: 14–23.
23.
Giletta M, Calhoun CD, Hastings PD, Rudolph KD, Nock MK, Prinstein MJ: Multi-level risk factors for suicidal ideation among at-risk adolescent females: the role of hypothalamic-pituitary-adrenal axis responses to stress. J Abnorm Child Psychol 2015; 43: 807–820.
24.
Henriksson MM, Aro HM, Marttunen MJ, Heikkinen ME, Isometsa ET, Kuoppasalmi KI, et al: Mental disorders and comorbidity in suicide. Am J Psychiatry 1993; 150: 935–940.
25.
Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002; 7: 254–275.
26.
Jokinen J, Nordstrom P: HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients. J Affect Disord 2009; 116: 117–120.
27.
Beck AT, Schuyler D, Herman I: Development of suicidal intent scales; in: Beck AT, Resnik HLP, Lettieri DJ (eds): The Prediction of Suicide. Bowie, Charles Press Publishers, 1974, pp 45–46.
28.
Träskman L, Åsberg M, Bertilsson L, Sjüstrand L: Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981; 38: 631–636.
29.
Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L: Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33: 14–22.
30.
Ferrari E, Cravello L, Muzzoni B, Casarotti D, Paltro M, Solerte SB, et al: Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates. Eur J Endocrinol 2001; 144: 319–329.
31.
Pivac N, Jakovljevic M, Muck-Seler D, Brzovic Z: Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Res 1997; 73: 123–132.
32.
Stanley B, Lones J: Risk for suicidal behaviour in personality disorders; in: Wasserman D, Wasserman C (eds): Oxford Textbook of Suicidology and Suicide Prevention. Oxford, Oxford University Press 2009, pp 287–292.
33.
Hawton K, Rodham K, Evans E: By their Own Young Hand: Deliberate Self-Harm and Suicidal Ideas in Adolescents. London, Jessica Kingsley Publishers, 2006.
34.
Hawes DJ, Brennan J, Dadds MR: Cortisol, callous-unemotional traits, and pathways to antisocial behavior. Curr Opin Psychiatry 2009; 22: 357–362.
35.
Jollant F, Bellivier F, Leboyer M, Astruc B, Torres S, Verdier R, et al: Impaired decision making in suicide attempters. Am J Psychiatry 2005; 162: 304–310.
36.
Jollant F, Lawrence NL, Olie E, Guillaume S, Courtet P: The suicidal mind and brain: a review of neuropsychological and neuroimaging studies. World J Biol Psychiatry 2011; 12: 319–339.
37.
McGirr A, Diaconu G, Berlim MT, Pruessner JC, Sable R, Cabot S, et al: Dysregulation of the sympathetic nervous system, hypothalamic-pituitary-adrenal axis and executive function in individuals at risk for suicide. J Psychiatry Neurosci 2010; 35: 399–408.
38.
Stengel E: Recent research into suicide and attempted suicide. Am J Psychiatry 1962; 118: 725–727.
39.
Linehan MM: Suicidal people. One population or two? Ann N Y Acad Sci 1986; 487: 16–33.
40.
Fushimi M, Sugawara J, Saito S: Comparison of completed and attempted suicide in Akita, Japan. Psychiatry Clin Neurosci 2006; 60: 289–295.
41.
Yehuda R: Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y Acad Sci 2009; 1179: 56–69.
42.
Panagioti M, Gooding PA, Tarrier N: A meta-analysis of the association between posttraumatic stress disorder and suicidality: the role of comorbid depression. Compr Psychiatry 2012; 53: 915–930.
43.
Krysinska K, Lester D: Post-traumatic stress disorder and suicide risk: a systematic review. Arch Suicide Res 2010; 14: 1–23.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.